Sandoz enters new era as standalone global leader in generic and biosimilar medicines
It is well placed for continued profitable growth as a standalone global leader in generic and biosimilar medicines.
- It is well placed for continued profitable growth as a standalone global leader in generic and biosimilar medicines.
- Sandoz Board Chairman Gilbert Ghostine says: "Today marks the dawn of a new era for Sandoz as an independent company, but our Purpose is unchanged: pioneering access for patients.
- Generics and biosimilars account for an estimated 80% of medicines used worldwide by volume, at about 25% of the total cost.
- Our refreshed brand reflects our enduring commitment to healthcare innovation and our dedication to meeting the global and local healthcare challenges head-on.